Prelude Therapeutics Stock Quote PRLD - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

2.04

Bid

1.73

Ask

2.04

Volume

0.00 Day's Range 0.00

1.66 52 Week Range 6.80

Market Cap

112.25M

Previous Close

2.04

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

284,749

Shares Outstanding

55,024,470

Dividend Yield

PE Ratio

-0.92

Earnings Per Share (EPS)

-2.21

Revenue

Net Profit

-121.83M

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.preludetx.com

Headquarters

Wilmington, Delaware, USA

Founded

Prelude Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PRLD. The last closing price for Prelude Therapeutics was $2.04. Over the last year, Prelude Therapeutics shares have traded in a share price range of $ 1.66 to $ 6.80.

Prelude Therapeutics currently has 55,024,470 shares outstanding. The market capitalization of Prelude Therapeutics is $112.25 million. Prelude Therapeutics has a price to earnings ratio (PE ratio) of -0.92.

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789...

Form 8-K - Current report

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST...

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.05	2.51256281407	1.99	2.08	1.86	139052	1.97957161	CS
4	-3.29	-61.7260787992	5.33	5.43	1.86	416108	2.5311445	CS
12	-4.06	-66.5573770492	6.1	6.8	1.86	284749	3.96743869	CS
26	-2.65	-56.5031982942	4.69	6.8	1.86	166065	4.02784312	CS
52	-0.78	-27.6595744681	2.82	6.8	1.66	153911	3.63630931	CS
156	-13.85	-87.1617369415	15.89	20.1099	1.66	169695	7.34716136	CS
260	-23.72	-92.0807453416	25.76	95.375	1.66	191294	19.06421066	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CTCXCarmell Corporation	$ 0.5125 (52.08%)	6.21M
BDSXBiodesix Inc	$ 2.44 (45.24%)	52
WWWW International Inc	$ 1.57 (35.34%)	2.7M
KZRKezar Life Sciences Inc	$ 0.8793 (18.82%)	588.08k
WATTEnergous Corporation	$ 0.70 (18.74%)	101
PALTPaltalk Inc	$ 2.46 (-19.87%)	2.22k
MLECMoolec Science SA	$ 0.7102 (-19.17%)	12.02k
NMHINatures Miracle Holding Inc	$ 0.1665 (-15.27%)	280.4k
RMCORoyalty Management Holding Corporation	$ 0.7865 (-14.70%)	800
OTRKOntrak Inc	$ 2.39 (-13.41%)	76.95k
KXINKaixin Holdings	$ 0.1982 (10.11%)	9.2M
CTCXCarmell Corporation	$ 0.5125 (52.08%)	6.21M
HAOHaoxi Health Technology Ltd	$ 0.1775 (0.28%)	5.57M
WWWW International Inc	$ 1.57 (35.34%)	2.7M
NVDANVIDIA Corporation	$ 134.41 (1.14%)	1.22M